A Phase 1 interventional study of SAR245408 (XL147) and MSC1936369B in Solid Tumors, sponsored by Sanofi. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-01.
Sponsored by Sanofi · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Neoplasm Metastasis by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Neoplasm Metastasis · Sanofi.
Among the 31 studies in Neoplasm Metastasis by Sanofi, this one is the 26th largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 1, and was the 24th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →1 of the 31 studies in Neoplasm Metastasis by Sanofi is open now, in 2 countries. Recruiting first, the newest first:
Blueprint Medicines Corporation · Sites in United States, Spain
Ages 18+
By country, each count listing its studies:
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 17 · Phase 3 9 · Phase 4 1
First in 1998; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 98 across the 31 interventional studies. Of the 29 that completed or were terminated, 12 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Neoplasm Metastasis by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objective:
The duration of the study will include a period for screening of up to a maximum of 28 days, a pretreatment evaluation period of up to 5 days, the on-treatment period, followed by a minimum of 30-day follow-up after the last study drug administration.
The patient may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal.
The study will have 2 parts:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with advanced solid tumors for which there is no approved or curative therapy:
Exclusion criteria:
The patient has previously been treated with a PI3K inhibitor or a Mitogen-activated protein extracellular signal-regulated kinase (MEK) inhibitor
The patient has received:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose escalation phase The starting dose of SAR245408 will be 25-mg once daily (up to 200-mg). The starting dose of MSC1936369B will be 15- mg once daily (up to 90-mg)
Drug: SAR245408 (XL147) · Drug: MSC1936369B
Pharmaceutical form:capsule and tablet Route of administration: oral
Pharmaceutical form:capsule Route of administration: oral
Identification of maximum tolerated dose
Time frame: up to 4 years
Number of participants with treatment emergent adverse events
Time frame: up to 4 years
Pharmakokinetic parameters of SAR245408: Cmax
Time frame: up to 4 years
Pharmakokinetic parameters of SAR245408: Tmax
Time frame: up to 4 years
Pharmakokinetic parameters of SAR245408:AUCι
Time frame: up to 4 years
Pharmakokinetic parameters of MSC1936369B: Cmax
Time frame: up to 4 years
Pharmakokinetic parameters of MSC1936369B: Tmax
Time frame: up to 4 years
Pharmakokinetic parameters of MSC1936369B: AUCι
Time frame: up to 4 years
The record gives a start of May 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.